Fludarabine

For research use only. Not for use in humans.

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

44 publications

Fludarabine Chemical Structure

Molecular Weight(MW): 285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 126 In stock
USD 97 In stock
USD 310 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Fludarabine has been cited by 44 publications

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  MkfrSpVv[3Srb36gRZN{[Xl? NGfkemczOCEQvF2= M1i3VlI1KGh? Mof0bY5pcWKrdIOg[ZhxemW|c3nvckBw\iCLRF:= M3Tu[lI2QTRyN{Gy
MV-4-11 MnjURZBweHSxc3nzJGF{e2G7 NG\HfnozNjVizszN NWnqbWlxPDhiaB?= Mn;GbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NVrXWIpSOjVzMUG1PFM>
THP-1 MlezRZBweHSxc3nzJGF{e2G7 Ml3tNk42KM7:TR?= NUPkO3JmPDhiaB?= MlrZbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= M4DLdVI2OTFzNUiz
MOLM 13 MojORZBweHSxc3nzJGF{e2G7 NYTlT|hCOi53IN88US=> M33BR|Q5KGh? M3XrSIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 Mof3NlUyOTF3OEO=
KBM3/Bu2506 NXjF[Gw1SXCxcITvd4l{KEG|c3H5 NEHqS3YzNjVizszN MnvBOFghcA>? MlKzbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NX:0cmR2OjVzMUG1PFM>
Nalm-6 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF6IN88US=> NYDDUZVROjVyNkGxNFE>
Reh MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDzTWM2OD1|MDFOwG0> MYOyOVA3OTFyMR?=
U2937 M3XkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fjcGlEPTB;MU[g{txO NVzwb2M1OjVyNkGxNFE>
Mec-1 NWD0[2lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHHUHBNUUN3MP-8olUxOCEQvF2= M2fMN|I2ODZzMUCx
RPMI-8226 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nGfWlEPTB;NUCwJO69VQ>? M3X3OFI2ODZzMUCx
Molt-4 NUi2V5ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF6MDFOwG0> M3HqZlI2ODZzMUCx
Nalm-6-FluR Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\EOmlEPTB;MkWwJO69VQ>? NXrJTHp1OjVyNkGxNFE>
Raji  MUTGeY5kfGmxbjDBd5NigQ>? M3f1dVPDqM7:TR?= M2nUdlI1NzR6L{eyJIg> M2nIOolv\HWlZYOgZYNkfW23bHH0bY9veyCxZjDwOVMtKHB4MzDhcoQheDd|wrC= NXfSd3FpOjR7NEC2PVU>
PBMC M{XZbWZ2dmO2aX;uJGF{e2G7 Ml:yOVAwOTByIN88US=> MV2yOEBp NIjVfIZFVVOR MVPpcohq[mm2czDTWGFVOSCyaH;zdIhwenmuYYTpc44> M4fE[|I1QTFzOEey
MDA-231 MlvvSpVv[3Srb36gRZN{[Xl? NY[3XWNkOTByIN88US=> MUCyOEBp M3rWNGROW09? NH7T[nhl\WO{ZXHz[ZMhUUSRIHX4dJJme3Orb36= MlSwNlQ6OTF6N{K=
624.38mel  NV\rfWFDTnWwY4Tpc44hSXO|YYm= NGnGVIY2OCEQvF2= MVOyOEBp NEDuUZdFVVOR NEHZOotl\WO{ZXHz[ZMhUUSRIHX4dJJme3Orb36= NY\iSoFyOjR7MUG4O|I>
MDA-231 MVLGeY5kfGmxbjDBd5NigQ>? MYi1NE0zODBizszN MorRNlQhcA>? NFnHRmlFVVOR MoHwbY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN? NWrN[VBJOjR7MUG4O|I>
624.38mel  MVLGeY5kfGmxbjDBd5NigQ>? MUG1NE0zODBizszN NYr3TJJWOjRiaB?= Mn\jSG1UVw>? NUK3ZmxWcW6qaXLpeJMhUUSRIHHjeIl3cXS7IHnu[IVx\W6mZX70cJkhd2ZibWLORUBt\X[nbIO= M3ztWVI1QTFzOEey
HMECs MWPGeY5kfGmxbjDBd5NigQ>? NYT5NIRQOTBywrFOwG3DqA>? MmDDN|bDqGh? MkTjbY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> MVKyOFIyOTN{Nx?=
HMECs  NYTPfnlETnWwY4Tpc44hSXO|YYm= MV2xNFDDqM7:TdMg MYCzOuKhcA>? M4Dr[YlvcGmkaYTzJGlHVs7zwrDt[YRq[XSnZDDwbI9{eGixconsZZRqd25ib3[gV3RCXDFiYX7kJHNVSVR|LDDieZQhdm:2IH;mJHNVSVR{ NXi4[VV2OjR{MUGzNlc>
BJAB M{PNcmFxd3C2b4Ppd{BCe3OjeR?= NY\tR|dKPcLizszN NVu1ZWpoOjRiaB?= MlXsbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MY[yOFA2PzF2Nx?=
I-83 MV7BdI9xfG:|aYOgRZN{[Xl? MXe1xsDPxE1? M2[0SlI1KGh? NWfFcoNqcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MmHoNlQxPTdzNEe=
NALM6 NH7ZclFCeG:ydH;zbZMhSXO|YYm= NIW2ZWc2yqEQvF2= M{HKb|I1KGh? NEjVeoFqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M2Ox[|I1ODV5MUS3
DU-145 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELrbmUxNTFyIN88[{9udA>? Mn3HOFghcMLi MVLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmXCNlM4OzR6MUW=
Nalm-6 MXPGeY5kfGmxbjDBd5NigQ>? M4\JTVExyqEQvF2= MYmxM|IwPCCq NYXLToJCcW6mdXPld{BifXSxcHjh[5k> NFvtZ4gzOzZ6MUKyNy=>
Reh NYDoWmZTTnWwY4Tpc44hSXO|YYm= NXPz[5U{OTEEoN88US=> NF21e28yNzJxNDDo NHG3elBqdmS3Y3XzJIF2fG:yaHHnfS=> M4HDfFI{PjhzMkKz
Nalm-6 M1HCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom5TWM2OCEkiMyxNQKBkc7:TR?= NUnQfIs4OjN4OEGyNlM>
Reh NX\UWoRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxKOLKvEGw5qCK|ryP NEHyS|AzOzZ6MUKyNy=>
HEC1A Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLINVAxNTVyMDFOwG0> M3\p[|I1KGh? M2Lhe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3HPUFI{PTl3Nkm3
AN3CA MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDYNVAxNTVyMDFOwG0> NI[xZWQzPCCq NWftdVBNcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmTYNlM2QTV4OUe=
HEC50B M3HSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[xNFAuPTByIN88US=> NUjDZoZsOjRiaB?= M3\neIlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 M2eyWVI{PTl3Nkm3
HEC1A NWTT[Gh6SXCxcITvd4l{KEG|c3H5 NV7PRZBXOjBxMUCwJO69VQ>? MV:yOEBp NV\Vb4ZLcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlnmNlM2QTV4OUe=
AN3CA MYnBdI9xfG:|aYOgRZN{[Xl? NEXrTlUzOC9zMECg{txO NYDsXXRkOjRiaB?= NUfC[ox[cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3fqelI{PTl3Nkm3
HEC50B Mnm0RZBweHSxc3nzJGF{e2G7 NGTTPYszOC9zMECg{txO Mmf4NlQhcA>? NHHzeodqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> M1Pr[lI{PTl3Nkm3
EHEB NVjZSYwySXCxcITvd4l{KEG|c3H5 NUPx[W9GPDBizszN NED0epgzPCCq Mk\hbY5lfWOnczDhdI9xfG:|aYO= M3zGTlI{PDl5MEe1
A549 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTF3LkhCtVIvQCEEtV2= NFO0bJYzOzN5N{G5Ni=>
A549 GAPDH-deficient Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;n[2NzUUN3ME2xPE42yrF{LkOgxtVO MnjFNlM{PzdzOUK=
CLL  NH;xNI9CeG:ydH;zbZMhSXO|YYm= NHvGSWMyOCEQvF5CpC=> MoPYNlQuQTZiaB?= MULpcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo M4G2TVIzOjB5Nki2
MEC1 MUHBdI9xfG:|aYOgRZN{[Xl? NV3RT2pPOTBywrFOwG0> M1HsOlczKGh? NF3oXmpqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NYfjVHRWOjJzM{K5O|M>
U937  M4ToN2Fxd3C2b4Ppd{BCe3OjeR?= M1TQUlAvQCEQvF2= NH32PFA1NTR6IHi= MoLCbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NIDJOIEzOjB5NEewNC=>
U937  NXvVcJoySXCxcITvd4l{KEG|c3H5 NY\aTYJYOSEQvF2= MWq5OkBp MmL5bY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= M4Hp[lIzODJ|NUKz
Daudi M1f6VWFxd3C2b4Ppd{BCe3OjeR?= M{O0XVIxKM7:TR?= NFLNb2c6PiCq MYXpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NVvRTJlsOjJyMkO1NlM>
J45.01 M1fNSWFxd3C2b4Ppd{BCe3OjeR?= NULQZpdvOSEQvF2= MYq5OkBp NHrvfllqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> MXuyNlAzOzV{Mx?=
RPMI 8226 NHzSUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJ3LkpCpOKyyqB|Lkeg{txO M{jJWFIyQTR6Mk[0
CEM NGTDUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;NfmlEPTB;Mj60xsDDucLiMD60JO69VQ>? MX6yNVk1QDJ4NB?=
Raji Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwNEhCpOKyyqByLkC0JO69VQ>? M37VWFIyQTR6Mk[0
U937 NFj1[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrTUVBqUUN3ME2wMlI1yqEEsdMgNE4xPCEQvF2= M{HNTlIyQTR6Mk[0
K562 M1TPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPCe|BkUUN3ME2wMlQ1yqEEsdMgNE4xPSEQvF2= NE\tWo4zOTl2OEK2OC=>
NALM-6 MWLBdI9xfG:|aYOgRZN{[Xl? M2fob|ExKM7:TdMg NEnJ[IczPCCq NXq2TGVpcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzcIlocHSueR?= Mn\1NlE3QTl|OEO=
JMV-3 NXj5NoxZSXCxcITvd4l{KEG|c3H5 NInqWHgyOCEQvF5CpC=> NF7tRoczPCCq MUjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOuaXfoeIx6 NWP6ZpFwOjF4OUmzPFM>
EHEB NX\IV4VVTnWwY4Tpc44hSXO|YYm= NYXTUXc3PS13MDFOwG0> NGLmNpMzPCCq Mlzo[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk> MUKyNVE3QDN7MR?=
JVM-2  MWDGeY5kfGmxbjDBd5NigQ>? MljIN|Ah|ryP MmLvNlQhcA>? MVnk[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25? MWGyNVE3QDN7MR?=
KBM3/Bu2506 NWPw[oNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnFeoZMUUN{ME2wMlY4KML3TR?= NYXQfHJlOjB7M{O1NFk>
KBM3/Bu2506 M2L4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSwMlYh|ryP MoPENlQhcA>? MYHpcoNz\WG|ZYOgeIhmKGOnbHyg[pJi[3Srb36gbY4hWy2yaHHz[S=> M1;rNVIxQTN|NUC5
MDA-MB-231 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\6TWM2OD12LkCg{txO NGfPRpgzODR2N{O5NC=>
MCF-7 NFHqb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPiVoxnUUN3ME2xOU4xKM7:TR?= MlSxNlA1PDd|OUC=
HLE-B3  M1XmUGZ2dmO2aX;uJGF{e2G7 Mn\lNlUh|ryP M4DuZlQ5KGh? MYHicI9kc3NiSV\OMe6{6oDVaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmGTzDlfJBz\XO|aX;u NWHETW54OjB2M{WxOVg>
K562 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWS3NkBp NF\EboRKSzVyPUOuN{BvVQ>? M{fsUlIxOzB5MUm4
BW-225 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|IxRTFwM{egx7cyOOLKkklCpO69VcLi NXy1NZdIOTh4NkGzPFA>
OH-65 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|IxRTFwM{egx7cyOOLKkklCpO69VcLi Ml;sNVg3PjF|OEC=
GR-145 NXTKb3E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLM[3FoUUN{ME2yMlc1KMPZIEGw5qiTQCBizszNxsA> M3;nU|E5PjZzM{iw
A549 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLkTWMzOD13LkS4JOOYKDFy4pkSPEDPxE4EoB?= MV2xPFY3OTN6MB?=
CaSki  M4TjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[3TWMzOD1zLkO3JOOYKDFy4pkSO{DPxE4EoB?= M1nJdFE5PjZzM{iw
ZMK-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|IxRTFwM{egx7chOTEkiKK2JO69VcLi NXroe|hxOTh4NkGzPFA>
SKW6.4 MmfORZBweHSxc3nzJGF{e2G7 MWmwMlAyNTFyIN88US=> MoPENlQwPDhiaB?= NFLNNpdqdmS3Y3XzJINmdGxiZHXheIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= NU[3OW9uOThyOUKzOFA>
RPMI 8226 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrWcJhWOjRiaB?= NEHETGZKSzVyPUGuOVTDqM7:TR?= M1P1UVE4QTd4MUi2
MM.1S MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j3XFQ5KGh? NWrWZY92UUN3ME2xN{41QMLizszN Mm\nNVc6PzZzOE[=
MM.1R NYHaXVYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\L[VQ5KGh? MmH5TWM2OD1|Mz63PUDPxE1? MkSzNVc6PzZzOE[=
U937 NFzqdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPPbFNKSzVyPUOsNlAxKMLzIEW2NEBvVQ>? MmXMNVU6OzB|NkG=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
procaspase-9 / procaspase-3; 

PubMed: 27223263     


Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control.

p-p53 / p53; 

PubMed: 27223263     


(A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒

STAT1; 

PubMed: 26677135     


Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.

27223263 26677135
Immunofluorescence
α-SMA / Vimentin; 

PubMed: 28322315     


FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).

28322315
Growth inhibition assay
Cell viability ; 

PubMed: 24956101     


CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.

24956101
In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Formulation: PBS
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
in solvent
Synonyms FaraA, Fludarabinum
Smiles NC1=NC(=NC2=C1N=C[N]2C3OC(CO)C(O)C3O)F

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03832127 Not yet recruiting Drug: 18F-Fludarabine Myeloma Nantes University Hospital|Cyceron April 1 2019 Phase 1
NCT03348033 Enrolling by invitation Biological: Chronic Myeloid Leukemia + NK cell Chronic Myeloid Leukemia Hospital de Clinicas de Porto Alegre March 2019 Phase 1|Phase 2
NCT03613532 Recruiting Drug: Venetoclax|Drug: Fludarabine|Drug: Busulfan Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia (CMML)|MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)|Hematopoietic Stem Cell Transplant Jacqueline Garcia MD|Dana-Farber Cancer Institute October 1 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

Related STAT Products

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID